Orca Bio's manufacturing facility in Sacramento, California. Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to prevent graft-versus ...

June 30 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Orca Bio's therapy for the treatment of ‌certain blood cancers, which also aims to lower the risk of stem cell ...

Affirmative therapy, or LGBTQ+ affirmative therapy, is a therapeutic approach that validates and advocates for the needs of sexual and gender minority individuals. Affirmative therapy employs a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. David Meek bought Bluebird Bio last year ...

Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell therapy gives ...

It will also explore common challenges encountered during scale-up and reveal strategies to ensure process consistency across all volumes. Additionally, Sepmag will offer some advice on monitoring the ...

This eBook outlines the seven key steps to successfully scaling up biomagnetic separation processes to allow you to better understand the scaling-up procedure. Sepmag develops smart and scalable ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

June 30 (Reuters) - The U.S. Food and Drug Administration has approved Orca Bio's cell therapy for the treatment of certain blood cancers, the regulator said on Tuesday. The therapy, called Orca-T, ...